Good News for Cancer and Heart Disease Patients: US Nuclear Partner Achieves Critical Milestone Proving New Way to Fill Multi-Billion/Year Shortage of Radioisotopes for Diagnostics and Treatments
- The National Academies of Sciences, Engineering, and Medicine warns about severe shortages of radioisotopes that are required to non-invasively diagnose heart disease, cancer, other health issues, and to treat over half of all cancers
- Radioisotopes are largely made in only 5 outdated and unreliable nuclear fission reactors that are all located outside the United States
- Supply chain effects not yet known as major radioisotope supplier, NRU Chalk River Reactor, was permanently shuttered a few months ago and is now being demolished
- US Nuclear and their partner MIFTEC Laboratories, have developed a revolutionary new way to produce large quantities of radioisotopes at about half the cost of today’s outdated and unreliable methods
- Critical “1010” milestone toward producing radioisotopes recently achieved by MIFTEC at University of Nevada, Reno National Terawatt Facility
NOW THERE IS GOOD NEWS FOR CANCER AND HEART DISEASE PATIENTS
- US Patent issue for radionuclide production using Z- pinch neutron source.
- Ongoing collaborations with the University of California, San Diego and the University of Nevada, Reno National Terawatt Facility for laboratory experiments and advancement of MIFTEC technology And planned actions:
- Planned production of Mo-99 using the safe, efficient, environmentally friendly and scalable Staged Z–Pinch technology, producing no long-term nuclear waste
- MIFTEC technology with the expected capability of providing the nuclear medicine industry with on-site isotope production at a cost savings of up to 50% of current facilities.”
Bob Goldstein, the CEO of US Nuclear, graduated from MIT with a degree in Physics and also has a degree in Engineering from Stanford. He has authored more than 40 white papers and presentations on radiation measurement and his work has been met and approved by US Federal standards set by the EPA, FDA, and NRC. He also works closely with Los Alamos, Sandia and Jefferson National Labs. His family’s first experience in nuclear physics goes back to the 1940s when his father was involved in the historic Manhattan Project that developed the atomic bomb.Mr. Goldstein founded US Nuclear and is known for delivering the most sensitive, accurate and reliable instruments in the world. The quality of their work is confirmed by a list of loyal and repeat customers such as NASA, the EPA, Department of Energy, U.S. Air Force, U.S. Army, U.S. Navy, MIT, Pacific Gas & Electric, General Electric, Lawrence Livermore, Oakridge National Lab and many more. US Nuclear has enjoyed a long-standing financial history of stable sales and modest profitability, but in 2017 the perfect storm or new and sustained growth spawned a sales increase of 50% with several new very large opportunities blossoming in the large and underserved radioisotope market and the environmental monitoring market that is forecast to hit $20 billion by 2021. For example, China is converting all of their coal-fired power plants that are responsible for dangerous polluted air and water, to about 200 fission nuclear reactors that all require the best radiation monitoring equipment in order to ensure safety. The Chinese nuclear agency claims that each individual nuclear power plant requires about $8,000,000 in the highest quality and most reliable radiation monitoring devices. With World Nuclear Power Organization’s forecast for a growing number of nuclear power plants to produce electricity (none planned to produce radio-isotopes), the demand for radiation monitoring devices also grows. Other large opportunities for US Nuclear are their unique products recently offered for radon mitigation in homes and offices and the use of drones to mount their sophisticated monitoring devices. Radon is commonly found in many homes and is one of the leading known causes of lung cancer. Goldman Sachs sees the drone market growing to a very large size by 2020.In conclusion, US Nuclear is enjoying strong growth from its core business, and on top of that, is well positioned to become a dominant supplier in a multi-billion-dollar healthcare market of radioisotopes. Goldstein says, “Given the failing state of essential medical isotope production facilities, this first-ever achievement to meet and exceed the 1010 milestone in fusion neutron production could not come at a better time. Additionally, the projected cost savings of up to 50% over the current imported resources; the idea of on-site production; the low cost and shorter time to build the generators, and the environmental benefit of a non-proliferating process that precludes the hazards of fission-based methods; should make for important upgrades ahead in the vital medical isotope supply chain.”
US Nuclear has enjoyed a long-standing financial history of stable sales and modest profitability, but in 2017 the perfect storm for new and sustained growth spawned a sales increase of 50% with several new very large opportunities blossoming in the large and underserved radioisotope market, and the environmental monitoring market that is forecast to hit $20 billion by 2021.